Well Referenced

Tag: active surveillance

Observations on the Doubling Time of Prostate Cancer: The Use of Serial Prostate-Specific Antigen in Patients with Untreated Disease as a Measure of Increasing Cancer Volume

This 1993 study evaluated PSA doubling times (PSADT) in 43 patients with untreated prostate cancer over an average of 30 months. The findings demonstrated that PSA levels increased in a log-linear (exponential) fashion, with doubling times varying significantly based on tumor stage and grade. Patients with higher-stage and higher-grade tumors

Read More »
June 26, 2025 No Comments

Re: Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer

This 2023 expert commentary discusses the 15-year follow-up results of the ProtecT trial, which compared active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. The trial found no statistically significant difference in prostate cancer-specific mortality among the three treatment modalities, with overall mortality remaining low across the

Read More »
June 26, 2025 No Comments

The Comparative Oncologic Effectiveness of Available Management Strategies for Clinically Localized Prostate Cancer

This 2017 review examines the comparative effectiveness of various treatment modalities for clinically localized prostate cancer, focusing on oncologic control. It evaluates radical prostatectomy, radiation therapy, and observation strategies, highlighting the trade-offs between treatment benefits and potential harms. The review also discusses emerging therapies such as cryotherapy and high-intensity focused

Read More »
June 26, 2025 No Comments

Long-term active surveillance for prostate cancer: answers and questions

This 2014 editorial by Dr. Matthew R. Cooperberg discusses the evolving role of active surveillance (AS) in managing low-risk prostate cancer. It emphasizes that AS is a viable strategy to avoid overtreatment and associated morbidities in men with indolent disease. The article highlights the need for standardized AS protocols, including

Read More »
June 26, 2025 No Comments

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

This 2020 prospective cohort study evaluated five-year patient-reported outcomes in 2,005 men with localized prostate cancer treated with active surveillance, prostatectomy, brachytherapy, or external beam radiation therapy (EBRT), with or without androgen deprivation therapy (ADT). Results showed that prostatectomy led to greater declines in urinary continence and sexual function, particularly

Read More »
June 26, 2025 No Comments

Active Surveillance for Intermediate Risk Prostate Cancer

This article reviews the role of active surveillance in managing intermediate-risk prostate cancer. It examines current evidence supporting the use of active surveillance for this patient group, considering factors like tumor characteristics, patient age, and life expectancy. The study suggests that active surveillance can be a reasonable alternative to aggressive

Read More »
June 26, 2025 No Comments

Active Surveillance for Low-Risk Prostate Cancer-An Evolving International Standard of Care

This article explores the evolving role of active surveillance in the management of low-risk prostate cancer. The study reviews international guidelines and clinical outcomes, highlighting the benefits of active surveillance in avoiding overtreatment and preserving quality of life. It emphasizes that with proper patient selection and monitoring, active surveillance is

Read More »
June 26, 2025 No Comments

Safety of Testosterone Therapy in Men with Prostate Cancer

This 2019 review by Morgentaler and Caliber examines the evolving perspective on testosterone therapy (TTh) in men with prostate cancer (PCa). Historically contraindicated, TTh is now considered a viable option for certain patients. The review discusses the “saturation model,” which suggests that prostate tissue’s response to androgens plateaus beyond a

Read More »
June 26, 2025 No Comments